Artelo Biosciences Analyst See It As An Emerging Biotech

Zinger Key PointsAnalyst Jason Kolbert upgrades Artelo to Buy with a new $20 price target citing multiple promising drug assets.ART12.11 matched Zoloft’s antidepressant effects in rats and outperformed it on cognitive outcomes in a preclinical study.From tariffs to inflation, macro risks are rising—Matt Maley reveals how he’s trading it all, live this Wednesday July 9 at 6 PM ET.D. Boral Capital upgradedArtelo Biosciences, Inc.ARTLon Tuesday.The analyst upgraded from Hold to Buy and introduced aprice forecast of $20.AnalystJason Kolbertwrote, “We continue to view Artelo as an emerging biotechnology company focused on Cachexia and chemotherapy-induced peripheral neuropathy (CIN) with the lead program.”ART27.13 is a Phase 2 asset, a selective benzimadazole agonist acquired fromAstraZeneca PlcAZN.The analyst wrote that ART27.13 showed potential to stimulate appetite and promote weight gain, which offered a novel approach to improving the quality of life of cancer patients.AstraZeneca invested millions to develop the drug. It was noted that a side effect was weight gain.ART26.12 is the second asset licensed from the University of Stonybrook.“ART26.12 appears to protect nerves from damage without compromising the efficacy of chemotherapy. While not the largest indication, it may be the one the company pursues based on time and cost to demonstrate definitive proof of concept data,” Kolbert wrote on Tuesday.In June, the companyannounced favorable resultsfrom its first-in-human study evaluating ART26.12. The results affirmed a promising safety and pharmacokinetic (PK) profile previouslyobserved in preclinical studies.On Monday, Artelo Biosciences announced the presentation of new preclinical data on its Cannabidiol and Tetramethylpyrazine cocrystal drug candidate, ART12.11, at the 35th Annual International Cannabinoid Research Society (ICRS) Symposium.Data Highlights:A 28-day treatment regimen with ART12.11 significantly reversed behavioral impairments in male rats exposed to chronic stress. The data with ART12.11 demonstrated efficacy on par with sertraline (Zoloft), a leading selectiveserotonin reuptake inhibitor (SSRI).Like sertraline, ART12.11 improved sucrose preference and social motivation, which are established behavioral markers of depressive-like states, to near-baseline levels.Unlike sertraline, ART12.11 reversed stress-induced deficits in both spatial and short-term memory without negatively impacting social memory.The company said these findings underscore ART12.11’s potential as a highly differentiated candidate for treating depression and anxiety, especially in patients where cognitive dysfunction occurs, which is a known limitation of existing SSRI therapies.ARTL Price Action:Artelo Biosciences stock is up 14.66% at $16.42 at publication on Tuesday.Loading...Loading...Read Next:IBM Aims To Simplify AI Deployment With New Chips, ServersPhoto: ShutterstockARTLArtelo Biosciences Inc$16.4214.7%Stock Score Locked: Edge Members OnlyBenzinga Rankings give you vital metrics on any stock – anytime.Unlock RankingsEdge RankingsMomentum95.92Price TrendShortMediumLongOverviewAZNAstraZeneca PLC$70.110.70%Market News and Data brought to you by Benzinga APIs© 2025 Benzinga.com. . .EarningsAnalyst RatingsOptionsDividendsIPOsdate▲▼ticker▲▼name▲▼Price Target▲▼Upside/Downside▲▼Recommendation▲▼Firm▲▼Click to see moreAnalyst RatingsupdatesAnalyst CalendarJoin Benzinga Edge and unlock all the major upgrades, downgrades, and changes to the market's most accurate analysts.Click to JoinPosted In:Analyst ColorBiotechCannabisNewsUpgradesHealth CareAnalyst RatingsMoversTrading IdeasGeneralBriefsD. Boral CapitalJason Kolbertwhy it's movingCannabis is evolving—don’t get left behind!Curious about what’s next for the industry and how to stay ahead in today’s competitive market?Join top executives, investors, and industry leaders at theBenzinga Cannabis Capital Conferencein Chicago on June 9-10. Dive deep intomarket-shaping strategies, investment trends, and brand-building insightsthat will define the future of cannabis.Secure your spot nowbefore prices go up—this is where the biggest deals and connections happen!Get your tickets today!